India Immuno-Oncology Drugs Market to be valued at US$ 550 Mn by 2030. Report: Industry Size, Y-o-Y Growth Rate, Epidemiology, Prevalence Rate

India Immuno-Oncology Drugs Market comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates present and past market values to forecast potential market management during the forecast period between 2024 - 2032.

Drugs For Oncology Market Outlook

The global market size for drugs for oncology is projected to grow significantly from USD 150 billion in 2023 to USD 300 billion by 2032, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.5%. This growth is driven by advancements in medical research, increasing prevalence of cancer, and the rising adoption of novel therapies. The escalating incidence of various cancer types, coupled with the growing geriatric population, is pushing the demand for effective cancer treatments, thus propelling the market.

One of the primary growth factors in the oncology drugs market is the continuous innovation and development of new therapies. The introduction of targeted therapies and immunotherapies has revolutionized cancer treatment, offering more effective and personalized treatment options. These advancements not only improve patient outcomes but also contribute to the market's expansion by creating new revenue streams for pharmaceutical companies. Moreover, the increasing focus on precision medicine and biomarker-driven treatments is expected to further drive market growth.

The rising prevalence of cancer globally is another significant driver for the oncology drugs market. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with an estimated 19.3 million new cancer cases and almost 10 million cancer deaths in 2020. This alarming increase in cancer incidence is driving the demand for effective treatment options. Governments and healthcare organizations are investing heavily in cancer research and awareness programs, further boosting the market for oncology drugs.

The growing geriatric population is also contributing to market growth. Older adults are more susceptible to cancer, and as the global population ages, the number of cancer patients is expected to rise. This demographic shift is increasing the demand for oncology drugs, particularly those that offer better efficacy and fewer side effects. Additionally, the expansion of healthcare infrastructure in developing countries and increased access to healthcare services are facilitating the adoption of advanced cancer treatments, thereby driving market growth.

Regionally, North America dominates the oncology drugs market, owing to its advanced healthcare infrastructure, high healthcare expenditure, and strong presence of key market players. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period. This is attributed to the increasing prevalence of cancer, improving healthcare infrastructure, and rising investments in healthcare. Governments in countries like China and India are focusing on enhancing cancer care services, which is expected to drive the market in this region.

Drug Class Analysis

The drugs for oncology market is segmented by drug class into chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others. Chemotherapy remains one of the most widely used cancer treatments, primarily due to its broad application across various cancer types. However, its use is gradually being overshadowed by the advent of more sophisticated treatments like targeted therapy and immunotherapy. These advanced therapies are designed to specifically attack cancer cells while sparing healthy tissue, thereby reducing side effects and improving treatment outcomes.

Targeted therapy has gained significant traction in recent years due to its precision and effectiveness. These drugs work by targeting specific molecules involved in cancer growth and progression, offering a more personalized treatment approach. The development of targeted therapies has opened new avenues for treating cancers that were previously difficult to manage, such as certain types of lung and breast cancers. The increasing approval of targeted drugs by regulatory authorities is expected to drive the growth of this segment.

Immunotherapy is another rapidly growing segment in the oncology drugs market. This innovative approach utilizes the body’s immune system to fight cancer, offering a novel treatment paradigm. Immunotherapies, including checkpoint inhibitors and CAR-T cell therapies, have shown promising results in treating various cancers, leading to their increasing adoption. The ongoing research and development activities in this field are likely to result in the introduction of new immunotherapeutic agents, further propelling market growth.

Hormonal therapy, which involves the use of hormones or hormone-blocking drugs t

Snapshot img { margin: 10px !important; } Immunotherapy Drugs Market Size 2025-2029

The immunotherapy drugs market size is forecast to increase by USD 220.8 billion, at a CAGR of 12.4% between 2024 and 2029.

The global immunotherapy drugs market is shaped by the persistent demand for more effective treatments for chronic conditions. The escalating incidence of cancer creates a significant need for innovative therapeutic approaches beyond traditional methods. This demand is being met by the ascendancy of personalized cancer vaccines, a key trend in the therapeutic vaccines space. These vaccines, which are a cornerstone of the cancer immunotherapy market, leverage a patient's unique tumor neoantigens to stimulate a targeted immune response, representing a significant move toward truly individualized oncology treatment.This advancement toward personalized medicine is creating a fertile ground for innovation and is a transformative force in the global fight against cancer. However, the substantial cost associated with these innovative treatments presents a considerable barrier to patient access. High prices create complex reimbursement landscapes for healthcare systems worldwide. This financial pressure, a key aspect of the immunosuppressants market, places a heavy burden on both patients and payers, a situation that is often compounded by the extended duration of many immunotherapy regimens.

What will be the Size of the Immunotherapy Drugs Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe ongoing evolution of the global immunotherapy drugs market is characterized by a deep exploration of the tumor microenvironment to inform the development of next-generation treatments. Research into overcoming therapeutic resistance mechanisms is leading to novel combination therapies and approaches designed to enhance clinical outcomes. These efforts are central to expanding the applicability of treatments in the broader immunology market and improving patient response rates across various indications.Advancements are particularly notable in the development of personalized cancer vaccines and the refinement of cell-based therapies. The application of logic-gated CAR T-cell therapies exemplifies the move toward greater precision and safety in the large molecule injectable drugs market. Concurrently, the development of bispecific antibodies that can engage multiple targets is opening new avenues for immune system modulation. These dynamics reflect a continuous push for more effective and targeted interventions within the cancer immunotherapy market.

How is this Immunotherapy Drugs Industry segmented?

The immunotherapy drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments. End-userHospitalsClinicsOthersTypeMonoclonal antibodiesVaccinesImmune checkpoint inhibitorsOthersTherapeutic areaCancerAutoimmune and inflammatory diseasesInfectious diseasesOthersGeographyNorth AmericaUSCanadaMexicoEuropeGermanyUKFranceItalyRussiaSpainThe NetherlandsAsiaRest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.Hospitals are the primary end-user for the administration of complex immunotherapy drugs, particularly novel treatments requiring significant infrastructure and specialized personnel. The intensive monitoring needed for therapies and the management of potential adverse effects, such as cytokine release syndrome, solidifies the central role of the hospital setting. However, the financial burden of these treatments is substantial, encompassing not only drug acquisition costs but also facility upgrades and specialized staff training, creating significant operational pressures.These financial and logistical challenges limit broader implementation, with reports indicating that only 16 percent of specialized centers have adequate access to certain advanced cell therapies. This pressure is a key factor driving hospitals to optimize treatment pathways and explore transitioning suitable patients to outpatient settings where feasible. Concurrently, hospitals are establishing dedicated immuno-oncology toxicity teams to manage adverse events, highlighting the need for specialized expertise to safely administer these potent therapies and incorporate new therapeutic options.

Request Free Sample

The Hospitals segment was valued at USD 103.3 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 45.6% to the growth of the global market during the forecast period.Technavio’s analysts have ela

Discover the explosive growth potential of the Indian granulocytes monoclonal antibody market by 2029. This in-depth analysis reveals key drivers, restraints, and market segmentation, offering valuable insights for investors and stakeholders in the oncology and immunology sectors. Explore projected market size, CAGR, and regional breakdowns to understand this lucrative opportunity.

Snapshot img

Humanized Mouse Model Market Size 2025-2029

The humanized mouse model market size is valued to increase USD 61.6 million, at a CAGR of 6.7% from 2024 to 2029. Growing adoption of personalized medicine will drive the humanized mouse model market.

Major Market Trends & Insights

North America dominated the market and accounted for a 33% growth during the forecast period.
By Product Type - GHMM segment was valued at USD 75.30 million in 2023
By End-user - Pharmaceutical and biotechnology companies segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 81.18 million
Market Future Opportunities: USD 61.60 million
CAGR : 6.7%
North America: Largest market in 2023

Market Summary

The market represents a dynamic and evolving landscape, driven by the growing adoption of personalized medicine and strategic alliances among key players. Core technologies, such as gene editing and transgenic engineering, continue to advance, enabling the creation of increasingly accurate and representative models for human diseases. Applications in drug discovery and Toxicology Testing are seeing significant growth, with humanized mouse models projected to account for over 40% of the total in vitro market share by 2025. However, limitations such as ethical concerns and high production costs pose challenges to market expansion.
Regulations, including those from the FDA and EMA, are continually evolving to address these concerns and ensure the ethical use and validation of these models. Regional markets, including North America and Europe, are expected to dominate due to strong investment in research and development and robust regulatory frameworks.

What will be the Size of the Humanized Mouse Model Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Humanized Mouse Model Market Segmented and what are the key trends of market segmentation?

The humanized mouse model industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product Type

  GHMM
  Cell-based humanized mouse model


End-user

  Pharmaceutical and biotechnology companies
  CROs
  Academic and research institutions


Application

  Oncology
  Immunology and infectious diseases
  Neuroscience
  Toxicology and hematopoiesis


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By Product Type Insights

The ghmm segment is estimated to witness significant growth during the forecast period.

Genetically modified mice, such as nod-scid and tumor xenograft models, play a pivotal role in preclinical drug development. Pharmacokinetic parameters are assessed through the use of these models to understand drug metabolism and efficacy. Conditional knockout mice, immunocompromised mice, and infectious disease models contribute significantly to disease pathogenesis studies. In cancer research, humanized immune system models, including autoimmune disease models and immunotherapy research, facilitate the investigation of tumor growth kinetics and immune response quantification. Serum biomarker analysis, histological analysis, and flow cytometry analysis are essential techniques used in the evaluation of pharmacodynamic parameters. Transgenic mouse models, therapeutic antibody testing, graft-versus-host disease studies, and scid mice models are integral to understanding survival rate analysis and cytokine production assays.

Metastatic potential studies provide valuable insights into the behavior of tumors and their response to treatments. Knockout mouse models and knockin mouse models are employed for the investigation of various diseases and conditions. The adoption of genetically humanized mouse models has seen a substantial increase, with approximately 30% of the global biopharmaceutical industry utilizing these models for research. Furthermore, industry experts anticipate a rise in demand for these models, with expectations of a 25% increase in adoption within the next five years. These trends reflect the continuous unfolding of market activities and the evolving patterns in molecular research and drug discovery.

Request Free Sample

The GHMM segment was valued at USD 75.30 million in 2019 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 33% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Se

India Custom Antibody Market size was valued at USD 7.5 million in 2024 and is projected to reach USD 21.2 million by 2032, growing at a CAGR of 14.1% from 2026 to 2032.According to Verified Market Research: the following drivers and trends are shaping the India Custom Antibody Market.Increasing R&D investments in biotechnology sector - Growing government funding and private sector investment in biotech research is driving demand for specialized antibody services, with pharmaceutical companies allocating larger budgets for drug discovery programs.Rising prevalence of chronic diseases - The surge in cancer, cardiovascular diseases, and autoimmune disorders in India is creating substantial demand for diagnostic and therapeutic antibodies, particularly for personalized treatment approaches.Growing adoption of precision medicine - Healthcare shift towards targeted therapies requires custom antibodies for specific biomarker identification and therapeutic targeting, driving market expansion in oncology and immunology applications.Expansion of contract research organizations (CROs) - The proliferation of CROs in India offering specialized antibody services to global pharmaceutical companies is creating new revenue streams and market opportunities.Technological advancements in antibody engineering - Innovations in recombinant antibody production, hybridoma technology, and purification methods are improving antibody quality while reducing production costs and timelines.

Explore the dynamic AFM Polyclonal Antibody market with key insights on growth drivers, CAGR, and regional trends from 2025-2033. Discover opportunities in university labs and business research institutes.

The global Polyinosinic-Polycytidylic Acid (Poly (I:C)) market is poised for significant expansion, projected to reach an estimated USD 312 million by 2025, driven by a robust compound annual growth rate (CAGR) of 5% over the forecast period of 2025-2033. This growth trajectory is largely attributed to the increasing recognition of Poly (I:C)'s potent immunostimulatory properties, making it an invaluable tool in vaccine adjuvant development and antiviral research. The pharmaceutical and laboratory sectors represent the primary applications, with significant demand for both Pharmaceutical Grade and Reagent Grade Poly (I:C). Advancements in biotechnology and a growing understanding of innate immunity are fueling its adoption in novel therapeutic strategies, including cancer immunotherapy and the development of broad-spectrum antiviral agents. The market is further bolstered by substantial investments in research and development by leading players, pushing the boundaries of Poly (I:C) applications and manufacturing processes. The market landscape is characterized by a competitive environment with both established global giants and emerging regional manufacturers. Key players like Thermo Fisher Scientific, Sigma-Aldrich, and InvivoGen are instrumental in supplying high-quality Poly (I:C) for research and development, while companies such as Shuanghe Pharmaceuticals and Baiyunshan Tianxin Pharmaceuticals are increasingly focusing on pharmaceutical-grade production for clinical applications. Geographically, the Asia Pacific region, particularly China and India, is expected to witness accelerated growth due to expanding biopharmaceutical industries and a rising demand for advanced research reagents. North America and Europe remain mature markets with a strong emphasis on innovation and the development of new therapeutic applications. While the market benefits from strong growth drivers, potential restraints could include stringent regulatory approvals for new drug formulations and the high cost associated with specialized production. Nevertheless, the continued exploration of Poly (I:C) in combating emerging infectious diseases and chronic illnesses ensures a promising outlook for the market. This report provides an in-depth analysis of the global Polyinosinic-Polycytidylic Acid (Poly(I:C)) market, encompassing historical trends, current dynamics, and future projections. The study spans a comprehensive Study Period of 2019-2033, with a Base Year and Estimated Year of 2025, and a detailed Forecast Period from 2025-2033, building upon Historical Period data from 2019-2024. The market is projected to reach significant monetary values in the millions, reflecting its growing importance.

The global Pharmaceutical Contract Manufacturing Organization (CMO) market is experiencing robust growth, projected to reach a substantial size with a Compound Annual Growth Rate (CAGR) of 6.53% from 2025 to 2033. This expansion is driven by several key factors. The increasing complexity of drug development, coupled with rising R&D costs, is pushing pharmaceutical companies to outsource manufacturing to specialized CMOs. This allows them to focus on core competencies like research and development while leveraging the expertise and economies of scale offered by CMOs. Furthermore, the growing demand for biologics and advanced therapies, particularly in areas like oncology and immunology, requires sophisticated manufacturing capabilities which many smaller pharmaceutical firms lack, thereby fueling the demand for CMO services. The market is segmented by service type (active pharmaceutical ingredients (API) including small and large molecules and high-potency APIs, and finished dosage forms such as solid, liquid, and injectable formulations), and secondary packaging, reflecting the diverse range of services offered. Geographic variations exist, with North America and Europe currently holding significant market shares due to established pharmaceutical industries and stringent regulatory frameworks. However, emerging markets in Asia, particularly China and India, are witnessing rapid growth driven by expanding domestic pharmaceutical sectors and increasing foreign investment. The competitive landscape is characterized by a mix of large multinational corporations and smaller specialized CMOs. Key players like Catalent, Recipharm, Jubilant Biosys, and Thermo Fisher Scientific (through Patheon) are major players, competing based on their technological capabilities, geographical reach, and specialized service offerings. The market's future growth will likely be influenced by factors such as technological advancements in manufacturing processes, increasing regulatory scrutiny, and the emergence of novel drug delivery systems. The continued shift towards outsourcing and the growing demand for specialized services will likely maintain the positive growth trajectory of the Pharmaceutical CMO market throughout the forecast period. Strategies focusing on innovation, technological advancements, and expansion into high-growth regions will be critical for CMOs to maintain competitiveness. Recent developments include: January 2023: Catalent announced that it had signed a development and license agreement with Ethicann Pharmaceuticals Inc., a Canadian/American specialty pharmaceutical company specializing in creating high-value cannabinoid drug therapies using Zydisorally disintegrating tablet (ODT) technology to advance Ethicann's clinical drug pipeline. Per the agreement, Catalent would use its Zydis technology to develop pharmaceutical products containing cannabidiol (CBD) and tetrahydrocannabinol (THC) for Ethicann's use in clinical trials for various conditions., March 2023: Biose Industria, a renowned leader in Live Biotech Process Development and Production (LBP), announced the opening of its new facility in Boston, Massachusetts. After Biose Industries' phenomenal success in developing and producing LBP processes and manufacturing worldwide, Biose's new facility will further strengthen its relationship with the US market., July 2023: Recipharm Opens New Analytical Laboratory in Bangalore, India, to Increase Global Testing Capabilities for Nitrosamines, Extractables, Leachables, and Elemental Impurity Testing. 5,000 Sq Ft. Laboratory will support Recipharm's existing analytical capacity to support biotech and pharma customers in the Research and Development of Oral Solids, Drug Delivery, Inhalation, Vaccine, and Injectables with Full cGMP Compliance.. Key drivers for this market are: Increasing Outsourcing Volume by Pharmaceutical Companies, Increasing Investment in Research and Development. Potential restraints include: Increasing Outsourcing Volume by Pharmaceutical Companies, Increasing Investment in Research and Development. Notable trends are: Active Pharmaceutical Ingredient (API) and Intermediates are Expected to Witness Robust Demand.